Immunohistochemical evaluation is not prognostic for recurrence in fully staged high-risk endometrial cancer
- 1 May 2002
- journal article
- research article
- Published by BMJ in International Journal of Gynecologic Cancer
- Vol. 12 (3), 286-289
- https://doi.org/10.1046/j.1525-1438.2002.t01-1-01103.x
Abstract
The objective of this study was to determine the prognostic significance of common immunohistochemical pathologic risk factors in fully staged high-risk endometrial cancers. Sixty-two of 265 consecutive endometrioid adenocarcinomas were considered high risk for recurrence because of deep myometrial invasion and poor differentiation (stage IC, G3), cervical metastasis (stage II), ovarian metastasis (stage IIIA) or lymph node metastasis (stage IIIC). All patients underwent complete surgical staging with bilateral pelvic and aortic lymphadenectomy. Expression of estrogen receptors, progesterone receptors, p53, HER-2/neu, c-myc, bcl-2, FVIII, and Ki-67 were analyzed by immunohistochemistry using commercially available monoclonal antibodies. A general linear model multiple regression analysis was used to determine if any of the immunostains, along with grade or stage, were predictors of recurrence. Mean age was 68 years and mean weight 188 pounds. Sixty-eight percent of patients had associated medical illness. The majority of tumors were poorly differentiated (44%) and were stage IIIC (29%). Mean follow-up was 4.3 years. Fourteen patients (22%) developed tumor recurrence. Using multiple regression analysis, none of the immunostains were predictive for recurrence (P = 0.19-.96). Only stage and grade were predictive of tumor recurrence (P = 0.04,.02). We conclude that in completely staged high risk endometrial cancer, commonly used immunohistochemical risk factors are not predictive for recurrence.Keywords
This publication has 12 references indexed in Scilit:
- Cancer statistics, 2000CA: A Cancer Journal for Clinicians, 2000
- Multidirectional Differentiation of Endometrial Carcinoma with Special Reference to Tumor Aggressiveness Evaluated by Ki-67 ExpressionGynecologic Oncology, 1999
- Lack of bcl-2 Persistence: An Independent Prognostic Indicator of Poor Prognosis in Endometrial CarcinomaGynecologic Oncology, 1998
- Genetic alterations in endometrial carcinomasInternational Journal of Gynecologic Cancer, 1998
- Prospective evaluation of the morbidity of complete lymphadenectomy in endometrial cancerInternational Journal of Gynecologic Cancer, 1998
- Prognostic Significance of Progesterone Receptor Immunohistochemistry in Endometrial CarcinomaGynecologic Oncology, 1998
- Relationship of Nonstaging Pathological Risk Factors to Lymph Node Metastasis and Recurrence in Clinical Stage I Endometrial CarcinomaGynecologic Oncology, 1997
- Angiogenesis in endometrial carcinomaCancer, 1997
- Epithelial and Stromal Estrogen and Progesterone Receptor Expression in Endometrial Cancer: True Color Computer-Assisted Image Analysis versus Subjective ScoringGynecologic Oncology, 1997
- Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: A gynecologic oncology group studyGynecologic Oncology, 1991